AstraZeneca’s RA Drug Disappoints – Analyst Blog

By | December 15, 2012
0 Comment

AstraZeneca ( AZN ) and its partner Rigel Pharmaceuticals ( RIGL ) recently announced top-line data from the phase IIb OSKIRA-4 study evaluating the use of oral fostamatinib for

Read more here:
AstraZeneca’s RA Drug Disappoints – Analyst Blog

Related posts:

  1. Merck’s Alzheimer’s Drug Progresses – Analyst Blog
  2. Encouraging Data on Glaxo’s Drug – Analyst Blog
  3. Ironwood Anxiety Drug in Phase I – Analyst Blog
  4. FDA Accepts Merck’s Sleep Drug NDA – Analyst Blog